Home - Products - Chromatin/Epigenetic - Epigenetic Reader Domain - SMARCA-BD ligand 1 for Protac

SMARCA-BD ligand 1 for Protac

CAS No. 1997319-92-2

SMARCA-BD ligand 1 for Protac( —— )

Catalog No. M33230 CAS No. 1997319-92-2

SMARCA-BD ligand 1 for Protac is a compound that binds to SMARCA2, the BAF ATPase subunit, utilizing Protac technology to degrade SMARCA2.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	140	In Stock
10MG	227	In Stock
25MG	385	In Stock
50MG	531	In Stock
100MG	724	In Stock
200MG	986	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

SMARCA-BD ligand 1 for Protac
Note

Research use only, not for human use.
Brief Description

SMARCA-BD ligand 1 for Protac is a compound that binds to SMARCA2, the BAF ATPase subunit, utilizing Protac technology to degrade SMARCA2.
Description

SMARCA-BD ligand 1 for Protac is a compound that binds to the BAF ATPase subunits SMARCA2, and used for degrading SMARCA2, based on PROTAC.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Chromatin/Epigenetic
Target

Epigenetic Reader Domain
Recptor

Epigenetic Reader Domain
Research Area

——
Indication

——

Chemical Information

CAS Number

1997319-92-2
Formula Weight

271.32
Molecular Formula

C14H17N5O
Purity

>98% (HPLC)
Solubility

——
SMILES

NC1=C(C=C(N=N1)C2=C(O)C=CC=C2)N3CCNCC3
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Farnaby W, et al. BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nat Chem Biol. 2019 Jul;15(7):672-680.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

FHT-1015

FHT-1015 is a potent SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor with potential anticancer activity for the study of cancer and inflammation.
BRD4-BD1-IN-2

BRD4-BD1-IN-2 is a selective and potent BRD4-BD1 inhibitor with an IC50 value of 2.51 μM, exhibiting 20-fold greater inhibitory activity against BRD4-BD1 compared to BRD4-BD2.
BY27

BY27, a potent and selective BET BD2 inhibitor (Ki: 3.1 nM) with anticancer activity, inhibits BD1/BD2 of BRD2, BRD3, BRD4, and BRDT, and suppresses tumor growth.

Sign In Join Free